Navigation Links
Accera, Inc. Names William T. Poncy Vice President of Commercial Development
Date:10/10/2007

BROOMFIELD, Colo., Oct. 10 /PRNewswire/ -- Accera Inc., a privately held biotechnology company focused on developing novel drugs for neurodegenerative diseases, today announced that it has appointed William T. Poncy, M.B.A., as vice president of commercial development. Mr. Poncy will direct the commercial launch of Ketasyn (AC-1202) as a medical food product in the U.S. for the treatment of Alzheimer's disease.

"Given his strong track record in all aspects pharmaceutical commercialization, we are thrilled to welcome Bill to our management team," commented Steve Orndorff, Ph.D., president and CEO. "We are confident that his strong track record combined with Ketasyn's excellent safety and efficacy will allow Accera to make a competitive entry into the multi billion-dollar Alzheimer's market."

Additionally, Mr. Poncy will be responsible for developing Accera's neurodegenerative disease franchise for ethical drugs now in development for Parkinson's disease, Huntington's disease, and age-associated memory impairment.

With more than 25 years of experience in the pharmaceutical industry, Mr. Poncy most recently served as vice president of sales and marketing at Myogen, Inc. (now Gilead Sciences), where he built the commercial organization and launched a pulmonary anti-hypertension franchise. Previously he was the North American vice president of sales and marketing for Pharmion Corp., where he developed an oncology commercial organization. He has also held positions in sales, managed care, trade, marketing and various management roles at DuPont Pharmaceuticals and Berlex Labs.

About Accera, Inc.

Based in Broomfield, CO, Accera, Inc. is a privately held biotechnology company focused on developing novel drugs for neurodegenerative diseases. The company's lead candidate, Ketasyn(TM) (AC-1202), is a first-in-class molecule that earlier this year completed successful Phase II clinical trials for Alzheimer's disease (AD) and age-associated memory impairment (AAMI). Accera plans to self-commercialize Ketasyn as a medical food for the treatment of AD in the US in 2008. A key element of Accera's strategy is work with corporate partners to commercialize Ketasyn in non-U.S. markets, and to develop AC-1202 and other proprietary small molecule compounds in its pipeline for a range of memory and cognition disorders associated with neurological conditions and aging. http://www.accerapharma.com

About Ketasyn(TM)

Brain imaging techniques performed on Alzheimer's patients reveal a dramatically decreased uptake of glucose, the brain's preferred source of energy. Known as neuronal hypometabolism, this condition resembles diabetes in the brain, or Type III diabetes. Ketasyn(TM) (AC-1202) is an orally available, liquid compound that is efficiently converted into ketone bodies, an alternative energy source that the brain can use even when glucose metabolism is impaired. By preserving glucose-deprived neurons, Ketasyn demonstrates neuroprotective and disease modifying potential in a number other neurodegenerative diseases characterized by neuronal hypometabolism. This first-in-class compound is also being evaluated in age-associated memory impairment, Parkinson's disease, and selected orphan drug indications.

About Medical Foods

The Food and Drug Administration defines a medical food as a food to be consumed or administered orally under medical supervision for the dietary management of a disease or condition for which specific nutritional requirements have been scientifically proven. Medical foods are specially formulated and processed to meet these nutritional requirements, which modification of the diet alone cannot satisfy. Medical foods may be prescribed by a physician for a patient actively receiving medical attention for a specific disease or condition, and are subject to the general food and safety labeling requirements of the Federal Food Drug and Cosmetic Act.

For information contact:

Meghan Feeks

Richard Lewis Communications, Inc.

212-827-0020

mfeeks@rlcinc.com


'/>"/>
SOURCE Accera Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Wisconsin IT association names Gee president, CEO
2. Quintessence Biosciences names new president
3. CDW names VP to handle Berbee merger
4. NimbleGen names CFO with capital-raising past
5. Cisco names Berbee a top partner of 2005
6. Cisco names Inacom most innovative partner
7. UW-Madison medical school names new dean
8. GE Healthcare names new CEO
9. Bruker AXS names new leadership
10. Sonic Foundry names new senior vice president
11. MyWeather names new president, marketing officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... LAKE, N.J. , Dec. 5, 2016 /PRNewswire/ ... Phase 3 open-label two-year study of rufinamide, which ... the American Epilepsy Society (AES) held from December ... Analysis of final two-year safety, tolerability and cognitive ... with rufinamide experienced similar safety and tolerability profiles, ...
(Date:12/4/2016)... -- In five studies being presented today during the 58th ... in San Diego , researchers are ... of life-saving treatments to patients with a variety of ... therapies directly to the sites in the body where ... advantage over traditional, systemic methods. The studies highlight the ...
(Date:12/2/2016)... Amgen (NASDAQ: AMGN ) and Allergan ... of a Marketing Authorization Application (MAA) to the European Medicines ... ® (bevacizumab). The companies believe this submission is the ... "The submission of ABP 215 to the EMA is ... portfolio," said Sean E. Harper , M.D., executive vice ...
(Date:12/2/2016)... ... December 01, 2016 , ... Aerocom Healthcare ( http://www.aerocomhealthcare.com ... will present its chain-of-custody solution for tracking and securing medications at booth 676 ... 4-8, 2016. , Aerocom has a proven solution for tracking medications via its ...
Breaking Biology Technology:
(Date:6/21/2016)... June 21, 2016 NuData Security announced today ... role of principal product architect and that ... of customer development. Both will report directly to ... The moves reflect NuData,s strategic growth in its ... high customer demand and customer focus values. ...
(Date:6/15/2016)... June 15, 2016 Transparency ... titled "Gesture Recognition Market by Application Market - Global Industry Analysis ... 2024". According to the report, the  global gesture recognition ... 2015 and is estimated to grow at a ... by 2024.  Increasing application of gesture ...
(Date:6/7/2016)... 2016  Syngrafii Inc. and San Antonio Credit ... includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution ... will result in greater convenience for SACU members ... maintaining existing document workflow and compliance requirements. ... Highlights: ...
Breaking Biology News(10 mins):